use it to make the public more aware of:
1. 25-percenters - the sickest patients, who often lead isolated and
impoverished lives, worsening over time,
And
2. Adolescents and young people. I would bet that XMRV poses a MUCH
greater threat to this cohort than AIDS or cancer.
Beware of falling into the trap of requiring XAND to equal CFS,
because it makes it all to easy to dismiss it - even without using
Reeves' cooked data sets. How many Cobbs Co., GA, "CFS" patients, or
how many patients with "fatiguing illnesses" have XAND? Not many. If
we allow the criteria for acceptance to focus on the ephemeral
concept CFS, we will lose.
I testified to the CFSCC about NMH/POTS, the 37kDa Rnase-L and HHV-6
(all of which I am so fortunate to have ...), and each time Straus
laughed and said "This has nothing to do with CFS" or "This is one of
many medical aberrations that have nothing to do with any disease,
certainly not CFS."
It was like shooting fish in a barrel for Straus or Reeves to quickly
patch together a study that "proved" there was no relationship
between CFS and [biomedical marker of choice].
Reeves is doing it now. We MUST have an answer for that rhetorical
distractor, this time around.
Mary Schweitzer, Ph.D.
Sent from my Verizon Wireless BlackBerry
---------------------------------------------
Send posts to CO-CURE@listserv.nodak.edu
Unsubscribe at http://www.co-cure.org/unsub.htm
Co-Cure Archives: http://listserv.nodak.edu/archives/co-cure.html
---------------------------------------------
Co-Cure's purpose is to provide information from across the spectrum of
opinion concerning medical, research and political aspects of ME/CFS and/or
FMS. We take no position on the validity of any specific scientific or
political opinion expressed in Co-Cure posts, and we urge readers to
research the various opinions available before assuming any one
interpretation is definitive. The Co-Cure website <www.co-cure.org> has a
link to our complete archive of posts as well as articles of central
importance to the issues of our community.
---------------------------------------------
